SCHEMBL2346609

SCHEMBL2346609

N=P(O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)O

nearest known ligand 0.47

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.47
BLM P54132 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
BTN3A1 O00481 3/20 0.35
MVD P53602 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2351336 0.97 FDPS (0.50) FDPSBLMTDP1BTN3A1MVD
SCHEMBL28494654 0.85 FDPS (0.64) FDPSBLMTDP1BTN3A1MVD
SCHEMBL45357 0.85 FDPS (0.64) FDPSBLMTDP1BTN3A1MVD
SCHEMBL36089 0.85 FDPS (0.64) FDPSBLMTDP1BTN3A1MVD
SCHEMBL897837 0.85 FDPS (0.64) FDPSBLMTDP1BTN3A1MVD
SCHEMBL28767268 0.85 FDPS (0.64) FDPSBLMTDP1BTN3A1MVD
SCHEMBL140392 0.85 FDPS (0.64) FDPSBLMTDP1BTN3A1MVD
SCHEMBL554667 0.85 FDPS (0.64) FDPSBLMTDP1BTN3A1MVD
SCHEMBL8851949 0.85 FDPS (0.64) FDPSBLMTDP1BTN3A1MVD
Triphosphate SCHEMBL28334675 0.85 FDPS (0.64) FDPSBLMTDP1BTN3A1MVD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4531867-B2 2010-08-25 JP claimed
EP-1450820-A4 METHOD FOR TREATING OR PREVENTING INFLAMMATORY DISEASES INSPIRE PHARMACEUTICALS INC (US) 2009-02-18 EP claimed
EP-1450820-A2 METHOD FOR TREATING OR PREVENTING INFLAMMATORY DISEASES Inspire Pharmaceuticals, Inc. (US) 2004-09-01 EP claimed
US-6596725-B2 Vision defects INSPIRE PHARMACEUTICALS, INC. 2003-07-22 US claimed
US-20030125299-A1 Method for treating or preventing inflammatory diseases PETERSON WARD M (US) 2003-07-03 US claimed
WO-2003039473-A2 METHOD FOR TREATING OR PREVENTING INFLAMMATORY DISEASES INSPIRE PHARMACEUTICALS, INC. (US) 2003-05-15 WO claimed
EP-0981534-A2 DINUCLEOTIDES AND THEIR USES Inspire Pharmaceuticals, Inc. (US) 2000-03-01 EP claimed
WO-1998034942-A2 DINUCLEOTIDES AND THEIR USE INSPIRE PHARMACEUTICALS, INC. (US) 1998-08-13 WO claimed
US-8008274-B2 P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating sinusitis INSPIRE PHARMACEUTICALS, INC. (US) 2011-08-30 US disclosed
EP-1450820-A4 METHOD FOR TREATING OR PREVENTING INFLAMMATORY DISEASES INSPIRE PHARMACEUTICALS INC (US) 2009-02-18 EP disclosed
EP-1450820-A2 METHOD FOR TREATING OR PREVENTING INFLAMMATORY DISEASES Inspire Pharmaceuticals, Inc. (US) 2004-09-01 EP disclosed
US-20030125299-A1 Method for treating or preventing inflammatory diseases PETERSON WARD M (US) 2003-07-03 US disclosed
WO-2003039473-A2 METHOD FOR TREATING OR PREVENTING INFLAMMATORY DISEASES INSPIRE PHARMACEUTICALS, INC. (US) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125299-A1 Method for treating or preventing inflammatory diseases ADORA2B, ADORA2A, P2RY2 FDPS 932/4885BLM 610/4885TDP1 2675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.